ADTL-SA1215
| Clinical data | |
|---|---|
| Drug class | Sirtuin-3 (SIRT3) activator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C26H29I2N2O3 |
| Molar mass | 671.338 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ADTL-SA1215 is a drug which acts as a sirtuin-3 (SIRT3) activator. It has been researched as a potential therapeutic agent for the treatment of triple negative breast cancer, as well as being used for basic research into the structure and function of the SIRT3 enzyme complex.[1][2]
References
- ^ Zhang J, Zou L, Shi D, Liu J, Zhang J, Zhao R, et al. (October 2021). "Structure-Guided Design of a Small-Molecule Activator of Sirtuin-3 that Modulates Autophagy in Triple Negative Breast Cancer". Journal of Medicinal Chemistry. 64 (19): 14192–14216. doi:10.1021/acs.jmedchem.0c02268. PMID 34605238.
- ^ Bursch KL, Goetz CJ, Smith BC (March 2024). "Current Trends in Sirtuin Activator and Inhibitor Development". Molecules. 29 (5): 1185. doi:10.3390/molecules29051185. PMC 10934002. PMID 38474697.